Key Takeaway: Nurix has announced the initiation of a Phase 1 clinical trial for its oral STAT6 degrader, aimed at treating type 2 inflammatory diseases. The company has generated about $139 million from its collaboration with Sanofi and is poised to receive up to $453 million in future milestone payments related to the STAT6 program.
Price reaction · baseline $23.22 (2026-08-03 close) · hit pre-market · clean, no other NRIX news in the window
day 0 close
+6.3%
day 1
+8.2%
day 3 · peak
+9.9%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix has initiated a Phase 1 clinical trial for a new STAT6 degrader.
The company has earned approximately $139 million from its collaboration with Sanofi.
Nurix is eligible for an additional $453 million in future milestones.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well
Frequently Asked Questions
What is the purpose of the STAT6 degrader trial?
The trial aims to evaluate the efficacy of an oral STAT6 degrader for type 2 inflammatory diseases.
How much has Nurix earned from its collaboration with Sanofi?
Nurix has earned approximately $139 million under its collaboration with Sanofi.
What future milestones can Nurix receive?
Nurix is eligible for approximately $453 million in future milestones related to the STAT6 program.
What phase is the STAT6 degrader currently in?
The STAT6 degrader has advanced into Phase 1 clinical trials.